Company Drug

3SBio Wins NMPA Approval for Eltrombopag Generic – TPO-RA Copycat Targets Novartis’ Revolade in China ITP/SAA Market

By Fineline Cube #3SBio #HKG: 1530 #Novartis #Product approvals

3SBio Inc. (HKG: 1530) announced NMPA marketing approval for its generic version of Novartis’ Revolade (eltrombopag olamine), an oral thrombopoietin receptor agonist (TPO-RA) for chronic immune thrombocytopenia (ITP) and severe aplastic anemia (SAA). The approval adds 3SBio to a crowded field of Chinese eltrombopag copycats, including Qilu Pharmaceutical, Kelun Pharmaceutical, and Chia Tai Tianqing, intensifying price competition in the growing thrombocytopenia market as the originator’s China exclusivity (market entry 2017) expires.

Regulatory Milestone

ItemDetail
AgencyNational Medical Products Administration (NMPA)
Approval TypeGeneric marketing authorization
ProductEltrombopag olamine tablets (generic)
Reference ProductRevolade (Novartis) – first approved U.S. 2008; China 2017
Drug ClassOral, small-molecule thrombopoietin receptor agonist (TPO-RA)
Indications• Chronic ITP (adults and pediatrics ≥6 years) – post-corticosteroid/immunoglobulin failure
• Severe aplastic anemia (SAA) – post-immunosuppressive therapy failure
Developer3SBio Inc. (HKG: 1530)
Competitive FieldQilu Pharmaceutical, Kelun Pharmaceutical, Chia Tai Tianqing (also approved)
Approval Date16 Mar 2026

Product Profile & Mechanism

AttributeEltrombopag Olamine Specification
MechanismThrombopoietin receptor (TPO-R) agonist; stimulates megakaryocyte proliferation and platelet production
RouteOral administration (daily)
Clinical OutcomesIncreases platelet counts; reduces bleeding risk; improves quality of life
Originator StatusNovartis Revolade – global blockbuster; ~$1.5 billion annual sales peak
Generic AdvantageLower cost vs. originator; improved access in price-sensitive China market

Market Context & Competitive Dynamics

FactorImplication
ITP Market SizeChina: ~100,000 diagnosed chronic ITP patients; growing diagnosis rates
SAA Market~5,000 annual new SAA cases; high unmet need; eltrombopag standard of care post-IST failure
Originator ExclusivityNovartis Revolade China launch 2017; ~8-9 years market exclusivity; now facing generic wave
Generic Competition4+ Chinese companies approved; price erosion 50-70% anticipated; volume-based procurement likely
3SBio PositioningEstablished biologics manufacturer (EPIAO, SEPO); adds small molecule oral portfolio; hospital formulary leverage

Competitive Landscape

CompanyProductStatusMarket Position
NovartisRevolade (originator eltrombopag)Marketed since 2017Brand premium; physician loyalty; pediatric experience
Qilu PharmaceuticalGeneric eltrombopagApprovedFirst-mover generic advantage
Kelun PharmaceuticalGeneric eltrombopagApprovedManufacturing scale; distribution strength
Chia Tai TianqingGeneric eltrombopagApprovedOncology portfolio synergy
3SBioGeneric eltrombopagApproved (March 2026)Biologics expertise; renal/hematology franchise fit

Strategic Outlook

PriorityTimelineStrategy
NRDL Negotiation2026-2027National reimbursement list inclusion critical for volume; price competition intensifies
Volume-Based Procurement2027+National tender likely; winner-take-most market dynamics
Hospital Formulary2026+Leverage 3SBio’s existing hematology/oncology relationships
Indication ExpansionOngoingPediatric ITP (≥6 years) and SAA marketing; real-world evidence generation
Global Potential2027+Emerging market export; WHO prequalification for ITP/SAA

Forward‑Looking Statements
This brief contains forward‑looking statements regarding pricing dynamics, market share capture, and competitive positioning for 3SBio’s eltrombopag generic. Actual results may differ due to volume-based procurement outcomes, physician prescribing patterns, and originator defense strategies.-Fineline Info & Tech

Related Post

Company Drug

Hengrui’s Irinotecan Liposome (II) Wins NMPA Phase II Approval – Adjuvant Pancreatic Cancer Study vs. Gemcitabine/Capecitabine

Fineline Cube
Company Drug

Chipscreen Biosciences’ CS08399 Wins NMPA Approval – PRMT5-MTA Inhibitor Targets MTAP-Deficient Solid Tumors and Lymphomas

Fineline Cube
Company Drug

Novartis’ Cosentyx Wins FDA Pediatric Approval – Only IL-17A Inhibitor for Hidradenitis Suppurativa in Adolescents 12+

Fineline Cube

You Missed

Company Drug

Hengrui’s Irinotecan Liposome (II) Wins NMPA Phase II Approval – Adjuvant Pancreatic Cancer Study vs. Gemcitabine/Capecitabine

Company Drug

3SBio Wins NMPA Approval for Eltrombopag Generic – TPO-RA Copycat Targets Novartis’ Revolade in China ITP/SAA Market

Company Drug

Chipscreen Biosciences’ CS08399 Wins NMPA Approval – PRMT5-MTA Inhibitor Targets MTAP-Deficient Solid Tumors and Lymphomas

Policy / Regulatory

China’s Basic Medical Insurance Covers 1.33 Billion in 2025 – NHSA Reports RMB 3.6 Trillion Fund Inflows, 114 New Drugs Added to NRDL